---

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): June 22, 2004

 

---

 

ANTARES PHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

 

---

 

Minnesota		0-20945		41-1350192
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

707 Eagleview Boulevard, Suite 414, Exton, PA 19341

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (610) 458-6200

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

---

---

Item 9. Regulation FD Disclosure.

 

Antares Pharma, Inc. (the “Company”) today made a presentation at its Annual Meeting of Shareholders regarding its operations and business. The PowerPoint slide presentation used during the Company’s presentation at its Annual Meeting of Shareholders is furnished as Exhibit 99.1

 

The information in this Item 9 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended.

 

Item 7. Financial Statements and Exhibits.

 

(c)

Exhibits.

 

99.1		PowerPoint Slides (furnished)

---

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 22, 2004		ANTARES PHARMA, INC.
		By		/s/ Lawrence M. Christian
				Lawrence M. Christian
				Chief Financial Officer